InternationalUSRemember you can easily switch between MIP US and MIP International at any time

European Commission claims pharma competition success

Legal Media Group


The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission

In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was conducted in 2008 to 2009.

That came as the total number of settlements reached 120 in 2011,...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

@TGraulund If anyone could explain the logic behind putting fees up by this amount, in current business environment, we'd be grateful!

May 29 2015 02:58 ·  reply ·  retweet ·  favourite
ManagingIP profile

Re-reading W-L v Actavis patent judgment http://t.co/niQjifQbcg & wondering about likelihood of appeal to @UKSupremeCourt Any views?

May 29 2015 10:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Wondering how much longer this will take ... #TPP https://t.co/lIqPx5MRLd

May 29 2015 10:27 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements